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INTRODUCTION
Cardiovascular diseases (CVD) are the most common cause
of death in European countries. They often lead to disability
and consequently to an increase in cost of health care. The
main cause of CVD is atherosclerosis which may begin in
childhood and remain asymptomatic for many years and
which progression depends mainly on modified risk factors
[1]. Although atherosclerotic complications are usually obse-
rved in adults, atherosclerosis begins in childhood and pu-
berty, which was confirmed by autopsy studies, published at
the beginning of the XXth century [2]. Recent studies based
on autopsy examinations of children who died suddenly (ac-
cidents, suicides), revealed a correlation between atheroscle-
rotic lesions in aorta or coronary arteries with known risk fac-
tors of CVD [3, 4]. In Bogalusa Heart Study as well as in Pa-
thobiological Determinants of Atherosclerosis in Youth Study
(PDAY) the range of damage to the aorta and coronary ves-
sels showed close relation to: body mass index (BMI), systolic
and diastolic blood pressure, cigarette smoking, level of lipo-
proteins and glycated haemoglobin. Finnish studies demon-
strated close relation between risk factors of CVD in childho-
od and an increase in common carotid artery intima-media
thickness (cIMT) in adults [5].
Cultural, social and economic changes in Poland have
contributed to higher prevalence of overweight and obesity
also in children population [6]. Obesity has become the com-
monest risk factor of CVD. The old stereotypes, that excess of
body weight in child favours its proper development is no
longer valid.  An obese child, as well as obese adult, is at high
risk of hyperinsulinaemia, impaired glucose tolerance, type 2
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diabetes mellitus, dyslipidaemia, hypertension and adverse
changes in blood vessel walls [7, 8]. Obesity in the develop-
mental age, especially in teenagers, predisposes not only to
obesity in adulthood but also is a strong factor leading to meta-
bolic syndrome [9]. Awareness of these facts should oblige
health care providers to implement obesity prophylaxis [10]. It
is recommended to propagate healthy lifestyle (proper nutri-
tion, i.e. elimination of fast food and crisps, limitation of swe-
ets, sweet drinks, and food with flavour additives as well as
more physical activity). A preventive factor is also breast fe-
eding of the neonate during first 6 months of life which lowers
the risk of obesity in later life, improves lipid profile and redu-
ces blood pressure and C-reactive protein level in children. It
seems that obesity prophylaxis should be started in prenatal
life through proper nutrition of pregnant woman. There are
data that both increased body mass of the foetus and intraute-
rine growth retardation may lead to development of obesity.
American Heart Association (AHA) in 2003 and 2007
published recommendations concerning the beginning of
primary prophylaxis of CVD connected with atherosclerosis
in children [11, 12]. Although there are no diagrams (such as
SCORE) to assess total risk in children population, the groups
of increased CVD risk were indicated in these documents. In
identification of high risk groups attention was paid to:
— positive family history with regard to obesity, hyperten-
sion, dyslipidaemia, diabetes mellitus and early occur-
rence of CVD and
— patient history with regard to the occurrence of: overwe-
ight or obesity, pre-hypertension or hypertension, dia-
betes mellitus, cigarette smoking and low physical activi-
ty (less than 60 minutes per day).
Screening with fasting lipid profile was recommended in
children over 2 years of age with a family history positive for
early CVD, dyslipidaemia and/or diabetes mellitus, in chil-
dren with unestablished family history and in children who
have other risk factors of CVD. If the mean lipids level based
on two fasting examinations exceeded the maximum value
(for total cholesterol: 170 mg/dL, LDL-cholesterol: 110 mg/dL),
it was recommended to start appropriate dietary treatment
and to increase physical activity. In case of significant dyslipi-
daemia, especially resistant to lifestyle modification for 6 to
12 months, consideration of pharmacological treatment was
recommended (after exclusion of secondary causes of dysli-
pidaemia, i.e. thyroid, liver or kidney diseases and diabetes
mellitus).
Another document by AHA accepted by the American
Academy of Paediatrics (AAP) is concerning children with high
risk of CVD [13]. Experts analysed available data about early
atherosclerosis and reactions to used management. Depen-
ding on pathological, clinical, pathophysiological or epide-
miological evidence for the presence of early atherosclerosis
a stratification protocol was established, where diseases were
classified into 3 risk groups (Table 1). In the highest risk group
(tier 1) are children who have pathological and/or clinical evi-
dence to be manifested as coronary disease before 30 years
of age. In this group the target level of LDL-cholesterol is
£ 100 mg/dL and HbA1c < 7%. Patients in tier 1 should mai-
ntain proper body weight and blood pressure < 90 percenti-
le. In the recommendations therapeutic lifestyle changes and
specific treatment for particular diseases was presented. In
children over 10 years of age with dyslipidaemia, statins were
recommended as first choice drugs. In patients with hyper-
tension, after 6 months of ineffective non-pharmacological
management, treatment with angiotensin-converting enzyme
inhibitor was recommended. Authors of these recommenda-
tions suggested that in the highest risk group management
similar to that as in secondary prevention in adults with con-
firmed coronary disease should be introduced.
Table 1. Disease stratification by cardiovascular risk [13]
Risk category Rationale Disease/condition
Tier 1 High risk Coronary artery disease manifestation Homozygous FH
< 30 years of age DM, type 1
Pathological and/or clinical evidence Chronic kidney disease/end-stage renal disease
Post-orthostatic heart transplantation
KD with current coronary aneurysms
Tier 2 Moderate risk Accelerated atherosclerosis < 30 years of age Heterozygous FH
Pathophysiological evidence KD with regressed coronary aneurysms
DM, type 2
Chronic inflammatory disease
Tier 3 At risk High-risk setting for accelerated atherosclerosis Post-cancer-treatment survivors
(coronary artery disease manifestation  > 30 years of age) Congenital heart disease
Epidemiological evidence KD without detected coronary involvement
FH — familial hypercholesterolaemia; DM — diabetes mellitus; KD — Kawasaki disease
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Educational projects involving CVD prophylaxis in chil-
dren and adolescents in Poland are currently implemented
by the National Program of Prophylaxis and Treatment of
Cardiovascular Diseases — POLKARD and Polish Forum for
Prevention [14, 15].
It should be emphasised that the present Guidelines are
first such document in Poland. We hope that it will help to
bring into life the motto of the European Heart Health Char-
ter: „Every child born in the new millennium has the right to
live until the age of at least 65 without suffering from avoida-
ble cardiovascular disease” [16].
GUIDELINES
1. Atherosclerosis may begin in childhood or early puber-
ty. The course is usually slow and asymptomatic and its
progression correlates with the number and intensity of
the same cardiovascular disease (CVD) risk factors as in
adults: body mass index (BMI), systolic and diastolic blo-
od pressure, concentration of the total cholesterol, low-
density lipoprotein cholesterol (LDL-C), high-density li-
poprotein cholesterol (HDL-C), triglycerides (TG) and
active or passive cigarette smoking.
2. The greatest risk of early development of CVD is obse-
rved in children and adolescents with familial hypercho-
lesterolaemia, diabetes mellitus, chronic kidney disease,
Kawasaki disease, chronic inflammatory diseases, and
congenital heart diseases and after heart transplantation
and cancer treatment. For each of these diseases CVD
events may occur in the first two decades of life.
3. The most common risk factor of CVD, i.e. overweight
and obesity, in the Polish paediatric population acco-
unts for 7 to 21% depending on the region, patient’s age
and criteria for diagnosis; in the recent years an increase
in the prevalence of this risk factor has been observed.
4. The prophylaxis of CVD in children and adolescents sho-
uld involve:
a. health education directed at the whole population,
b. identification of groups at increased risk,
c. intervention in the groups of increased risk.
5. Recommendations for all children and adolescents
include:
a. a proper diet, to enable normal growth and develop-
ment of the child and to maintain ideal body weight,
blood pressure and lipid profile. Calorie intake should
be adjusted to meet demand. Consumption of vegeta-
bles and fruit, whole grains, dairy products, fish, nuts,
poultry and lean meat is recommended. Fat intake sho-
uld be unrestricted up to the age of 2 years. Afterwards it
is recommended to limit foods high in: saturated fats
< 10% of calories per day, trans-fatty acids < 1% of ca-
lories per day, salt intake < 6 g per day and monosac-
charides,
b. avoidance of smoking and staying away from places
where people smoke,
c. increase in physical activity to at least 60 minutes per
day and limitation of time spending in front of a screen
(television, DVD, computer) to at most 2 hours per day.
Parents, teachers, doctors and other health care workers
must participate in healthy lifestyle promotion.
6. Identification of groups at high risk of CVD is based
on:
a. a family history to establish premature (before 55 years
of age) development of CVD and/or risk factors of CVD
in the closest relatives (severe hypercholesterolaemia, hy-
pertension, metabolic syndrome, diabetes),
b. regular assessment of weight, height and BMI,
c. measurement of blood pressure at least once a year in
children over 3 years of age, using appropriate cuff size,
d. evaluation of a lipid profile in children over 2 years of
age with positive family history for dyslipidaemia or early
CVD and in children in whom other risk factors are pre-
sent or family history is unknown. If lipid profile is nor-
mal it is recommended to repeat the test every 3–5 years
e. evaluation of glucose level after 2 hours in oral glucose
tolerance test in obese children every 2 years,
f. regular (at least once a year) estimation of passive or ac-
tive cigarette smoking,
g. regular (at least once a year) evaluation of physical activity.
7. The aim of intervention is to eliminate or reduce nega-
tive effects of identified risk factors. In this intervention
a close cooperation between doctors and parents as well
as acceptance from a child are necessary. CVD preven-
tion should begin early in the developmental age.
8. The target levels of risk factors in children and adole-
scents:
a. LDL-C < 130 mg/dL (if possible < 110 mg/dL) and <
100 mg/dL in people at the highest risk of CVD (children
with familial hypercholesterolaemia, diabetes mellitus,
chronic kidney disease, after heart transplantation and
with Kawasaki disease with coronary artery aneurysms),
b. TG < 150 mg/dL,
c. HDL-C > 40 mg/dL,
d. blood pressure < 95 percentile for age, sex and height
or < 90 percentile for age, sex and height in case of co-
existence of risk factors of CVD as well as in patients at
the highest risk of CVD (see 8a),
e. BMI < 90 percentile for age and sex,
f. glucose levels as in adults (see Polish Forum for Preven-
tion Guidelines for diabetes mellitus), HbA1c < 6.5%.
In case of risk factor’s levels above the targets, the first
step is to recommend a change in lifestyle. If no effect is
observed, secondary causes of disorders should be lo-
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9. Non-pharmacological treatment:
a. diet:
— limited intake of:
I. saturated fats (< 7% calories), trans-fatty acids < 1%
calories and total cholesterol (< 300 mg per day) in
case of elevated level of LDL-cholesterol,
II. monosaccharides if there is hypertrigliceridaemia,
III. salt.
— alcohol abstinence,
— increased consumption of vegetables and fruit.
Collaboration with a trained dietician is recommended.
b. increased physical activity
c. weight reduction. For overweight or obese children a we-
ight management program should be initiated and direc-
ted at all family members who are overweight or obese,
d. complete cessation of smoking for children and parents
who smoke. All tobacco users should be advised to quit
smoking and to stay away from places where cigarettes
are smoked.
10. Pharmacological treatment. If change of lifestyle does
not bring adequate effects after 6–12 months, pharma-
cological treatment should be considered:
a. of hypercholesterolaemia if:
— LDL-C > 190 mg/dL in children without risk factors,
— LDL-C > 160 mg/dL in children with a family histo-
ry positive for early CVD or ≥ 2 other risk factors,
— LDL-C > 130 mg/dL in patients with diabetes mellitus.
The drug of choice is statin (for boys ≥ 10 of age and
girls after puberty). A consultation with the centre expe-
rienced in dyslipidaemia treatment is recommended.
b. of hypertrigliceridaemia, when fasting TG > 700 mg/dL
to diminish the risk of acute pancreatitis. Fibrates or ni-
cotinic acid (in children ≥ 10 of age) and omega-3 fatty
acids are used. A consultation with the centre experien-
ced in dyslipidaemia treatment is recommended,
c. of hypertension. The indication to begin pharmacothe-
rapy, regardless of lifestyle changes, is symptomatic or
secondary hypertension, evidence of organ damages
(heart, kidneys, retina) and accompanying diabetes mel-
litus or chronic kidney disease.
Patients with the highest risk of CVD development re-
quire individual therapeutic approach.
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